CardioComm Solutions to Settle Outstanding Debt With Shares
CardioComm Solutions to Settle Outstanding Debt With Shares
Toronto, Ontario--(Newsfile Corp. - June 3, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it will enter into debt settlement agreements with certain creditors of the Company, pursuant to which the Company will issue an aggregate of 41,834,010 common shares of the Company ("Shares") to the creditors at a deemed price of $0.01 per Share to settle an aggregate of $418,340.10 in outstanding debt owed by the Company. The debt to be settled includes retiring $345,261.46 in structured debt and $73,078.64 in operational debt. When issued, the Shares will be subject to a four month hold period in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The debt settlement transactions and the issuance of the Shares thereunder is subject to receipt of approval from the TSX Venture Exchange.
安大略省多倫多--（newsfile corp. - 2024年6月3日）--CardioComm Solutions, Inc. (tsxv: EKG) (“CardioComm”), 是一家提供全球貨幣消費性心臟監測和醫療心電圖(“ECG”)軟件解決方案的公司，欣然宣佈將與公司的某些債權人進入債務清算協議，根據該協議，公司將以0.01美元的平均價格發行累計41834010股公司的普通股(“股份”)給債權人，以清償公司拖欠的累計418340.10美元的債務。待發行的股票將依據適用證券法和tsx Venture Exchange的政策，受到持有期爲四個月的限制。債務清算交易和其下發行的股份需要獲得tsx Venture Exchange的批准。CardioComm"或"公司”），是一家提供全球貨幣消費性心臟監測和醫療心電圖(“ECG”)軟件解決方案的公司，欣然宣佈將與公司的某些債權人進入債務清算協議，根據該協議，公司將以0.01美元的平均價格發行累計41834010股公司的普通股(“股份”)給債權人，以清償公司拖欠的累計418340.10美元的債務。待發行的股票將依據適用證券法和tsx Venture Exchange的政策，受到持有期爲四個月的限制。債務清算交易和其下發行的股份需要獲得tsx Venture Exchange的批准。ECG”軟件解決方案，是一家提供全球貨幣消費性心臟監測和醫療心電圖(“ECG”)軟件解決方案的公司，欣然宣佈將與公司的某些債權人進入債務清算協議，根據該協議，公司將以0.01美元的平均價格發行累計41834010股公司的普通股(“股份”)給債權人，以清償公司拖欠的累計418340.10美元的債務。待發行的股票將依據適用證券法和tsx Venture Exchange的政策，受到持有期爲四個月的限制。債務清算交易和其下發行的股份需要獲得tsx Venture Exchange的批准。股份”）給債權人，以清償公司拖欠的累計418340.10美元的債務。待發行的股票將依據適用證券法和tsx Venture Exchange的政策，受到持有期爲四個月的限制。債務清算交易和其下發行的股份需要獲得tsx Venture Exchange的批准。
Certain directors of the Company participated in the debt settlement transactions, and each transaction with a director is considered to be a "related party transaction" as defined under Multilateral Instrument 61-101 ("MI 61-101"). Each transaction with a director of the Company is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of each transaction does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101.
公司的某些董事參與了債務清算交易，與每個董事的交易都被視爲多邊協議61-101（“mi 61-101”）下定義的“相關方交易”。與公司董事的每筆交易均因其公平市場價格不超過公司市值的25%而免於mi 61-101的形式評估和少數股東批准要求。mi 61-101的形式評估和少數股東批准要求，因爲每筆交易的公平市價不超過公司市值的25%，均與公司的董事免於mi 61-101的形式評估和少數股東批准要求。
To learn more about CardioComm's products and for further updates regarding HeartCheck ECG device integrations please visit the Company's websites at and .
要了解有關CardioComm產品的更多信息以及有關HeartCheck ECG設備集成的更多更新，請訪問公司網站。
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).
關於CardioComm Solutions
CardioComm Solutions的專利和專有技術用於記錄、查看、分析和存儲心電圖，以診斷和管理心臟患者。這些產品通過外部分銷網絡和北美銷售團隊的組合在世界範圍內銷售。CardioComm Solutions已獲得ISO 13485認證，是HIPAA合規的，並獲得了歐盟(CE標記)、美國(FDA)和加拿大(Health Canada)的批准。
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
欲了解更多信息請聯繫：
Etienne Grima，首席執行官
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
前瞻性聲明
本新聞稿中包括的關於未來表現和結果、預期、規劃、策略、重點、承諾和其他聲明（包括與我們社會、環境和其他可持續性目標有關的聲明）的非歷史事實的前瞻性聲明，是根據美國聯邦證券法的定義而作出的前瞻性聲明。本新聞稿中關於我們環境和其他可持續性計劃和目標的前瞻性聲明以及其他聲明並不意味着這些聲明對於投資者、我們的業務、運營結果、財務狀況、前景或策略、對我們在可持續發展事項上的影響或其他當事方來說均是重要的，或者必須披露在我們向證券交易委員會（“SEC”）或其他監管機構的備案中。此外，歷史、現有及未來涉及社會、環境和可持續性的相關聲明可能是基於仍在發展的衡量進展的標準、不斷演變的內部控制和流程以及假設，在將來可能會發生變化。前瞻性聲明基於當前的信仰、期望和假設，並受到可能導致實際結果與前瞻性聲明有實質性差異的重大風險、不確定性和情況變化的影響。
本發佈可能包含某些前瞻性聲明和與CardioComm Solutions的財務狀況、經營業績和業務有關的某些前瞻性信息以及CardioComm Solutions關於這些項目的某些計劃和目標。這些聲明和信息反映了管理層的目前信仰，並基於目前可供管理層使用的信息。nature，forward-looking statements and forward-looking information involve risk and uncertainty因爲forward-looking statements和forward-looking information涉及到將來會發生的事件和情況,並且有很多因素可能會使實際結果和發展與這些forward-looking statements和forward-looking information所表達或暗示的結果和發展有所不同。
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
在評估這些聲明時，讀者不應過多依賴前瞻性聲明和前瞻性信息。除適用法律要求，包括但不限於51-102國家法令第5.8(2)條款，本公司將不承擔更新在本次發佈中包含的前瞻性聲明和前瞻性信息的責任，而其他的行爲須履行適用法律要求。持續披露義務).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
TSX Venture Exchange及其監管服務提供者（如TSX Venture Exchange的政策中所定義的那樣）均不對本發佈的充分性或準確性承擔責任。
譯文內容由第三人軟體翻譯。